logo
logo

Convergent Therapeutics announced it raised $29.2 Million in an initial filing from an offering of $99.2 Million

Convergent Therapeutics announced it raised $29.2 Million in an initial filing from an offering of $99.2 Million

05/22/23, 7:25 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgcambridge
Money raised
$29.2 million
Industry
biotechnology
health care
therapeutics

Company Info

Company
Convergent Therapeutics
Location
cambridge, massachusetts, united states
Additional Info
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.

Related People